Regeneron stock target raised to USD 865 ahead of Xetra open
Published on 10/20/2026 at 07:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPiper Sandler updates its target
- On October 19, Piper Sandler lifted its Regeneron target to USD 865 from USD 854 and retained an Overweight rating.
- Regeneron’s investor site lists 16 approved medicines developed in-house.
- Regeneron stock trades pre-market at EUR 697.85 at 7:56 a.m. CEST at Lang & Schwarz on October 20, 2026.
On October 19, 2026, Piper Sandler raised its price target for Regeneron from USD 854 to USD 865 while maintaining an Overweight rating, according to Markets Insider. The report said the firm reassessed sales estimates and updated model assumptions ahead of Regeneron’s third-quarter results.
Piper Sandler updates its view
The analyst action lifts the target by USD 11 and leaves the stated rating unchanged. The report identified Piper Sandler as the source of the revised target and rating.
Ahead of the Xetra open
Regeneron stock trades pre-market at EUR 697.85 at 7:56 a.m. CEST at Lang & Schwarz on October 20, 2026. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Regeneron stock.
How Regeneron makes its money
Regeneron develops medicines by combining scientific research and development with the commercialization of treatments for serious diseases, according to its company website. The site lists 16 approved medicines developed in-house and nearly 50 candidates in development. Market context: Market report S&P 500.
